Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8126668 | 0.85 | MAPK1 (0.54) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL10639259 | 0.83 | POLB (0.49) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL8171565 | 0.83 | POLB (0.46) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL3373963 | 0.83 | POLB (0.63) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL7247406 | 0.82 | XDH (0.46) | POLBHTTMAPK1KMT2ATP53 | |
| SCHEMBL14005999 | 0.81 | POLB (0.66) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL2733465 | 0.80 | POLB (0.60) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL7195630 | 0.80 | CYP11B1 (0.56) | POLBHTTMAPK1KMT2ASRC | |
| SCHEMBL15613780 | 0.77 | POLB (0.44) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL7252343 | 0.74 | MAPK1 (0.40) | POLBHTTMAPK1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0146228-B1 | SUBSTITUTED 2-MERCAPTO-IMIDAZOLES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1988-01-20 | — | — | EP | claimed |
| US-4584383-A | Substituted 2-mercapto-imidazoles and their preparation | FARMOS YHTYMA-OY (FI) | 1986-04-22 | — | — | US | claimed |
| EP-0146228-A1 | Substituted 2-mercapto-imidazoles and their preparation and use | Farmos-Yhtyma Oy (FI) | 1985-06-26 | — | — | EP | claimed |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | disclosed |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | disclosed |
| EP-2725024-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-04-30 | — | — | EP | disclosed |
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2013000267-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 中国科学院上海药物研究所 (CN) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013000108-A1 | AZOLE HETEROCYLIC COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国科学院上海药物研究所 (CN) | 2013-01-03 | — | — | WO | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
| US-6630593-B1 | A process for preparing a 1-substituted 5-hydroxymethylimidazole of the formula: wherein R represents alkyl, hydroxyalkyl, allyl, or substituted or unsubstituted arylmethyl or diarylmethyl, comprising the step of reacting a | LG CHEM INVESTMENT LTD. (KR) | 2003-10-07 | — | — | US | disclosed |
| EP-1255737-A4 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG CHEM INVESTMENT LTD (KR) | 2003-04-16 | — | — | EP | disclosed |
| EP-1255737-A1 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG Chem Investment, Ltd. (KR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001017974-A1 | PROCESS FOR PREPARING A 1-SUBSTITUTED 5-HYDROXYMETHYL IMIDAZOLE | LG CHEM INVESTMENT LTD. (KR) | 2001-03-15 | — | — | WO | disclosed |
| US-6140508-A | USEFUL IN THE PREPARATION OF FARNESYL-PROTEIN TRANSFERASE INHIBITORS. | MERCK & CO., INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0146228-B1 | SUBSTITUTED 2-MERCAPTO-IMIDAZOLES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1988-01-20 | — | — | EP | disclosed |
| US-4584383-A | Substituted 2-mercapto-imidazoles and their preparation | FARMOS YHTYMA-OY (FI) | 1986-04-22 | — | — | US | disclosed |
| EP-0146228-A1 | Substituted 2-mercapto-imidazoles and their preparation and use | Farmos-Yhtyma Oy (FI) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | PLA2G5, LTA4H, PLA2G4A | POLB 3703/4885HTT 3470/4885MAPK1 3816/4885 |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | POLB 2063/4885HTT 1887/4885MAPK1 1615/4885 |
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | POLB 2063/4885HTT 1887/4885MAPK1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.